% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

  • sigakingone sigakingone Mar 4, 2013 10:33 PM Flag

    ot: Sarepta’s stock has shot up from a low of $2.60 a year ago to $29.82 as of Monday at 2 p.m.


    Mar 4, 2013, 2:32pm EST
    Sarepta reports positive pre-clinical data on Marburg virus candidate

    Sarepta Therapeutics Inc. (Nasdaq: SRPT) says that in animal studies the drug it’s developing to fight a potential bioterrorism agent called Marburg virus has been shown to be as effective when injected into muscles as it is into the bloodstream.

    Marburg hemorrhagic fever has no effective treatments, and has been classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention (CDC).
    Sarepta, which specializes in gene-based drugs, received a $3.9 million contract from the Department of Defense in August 2012 for pre-clinical tests of AVI-7288 as administered intravenously. The contract is expected to be completed by the second half of this year, and the DoD has the option to extend it.
    While the company intended to develop and commercialize its DMD drug candidate, eteplirsen, on its own, the Marburg program is being done in conjunction with the government and, if successful, would be stockpiled in case of an outbreak, the company said.
    Sarepta’s stock has shot up from a low of $2.60 a year ago to $29.82 as of Monday at 2 p.m.


    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.95-0.0700(-2.32%)12:32 PMEDT